



Our File No. 09800080-0174

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Shimkets *et al.*

Application No.: 10/722,292

Filed: November 25, 2003

For: METHOD OF DETECTING
CARDIAC HYPERTROPHY
THROUGH PROBE
HYBRIDIZATION AND GENE
EXPRESSION ANALYSIS

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

Submitted herewith is an Information Disclosure Statement for consideration in the above-identified application. This Information Disclosure Statement is submitted:

- ☒ Within 3 months (1) of filing date of a national application; (2) of date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; or (3) before the mailing date of a first Office Action on the merits, whichever occurs last. (No fee is required.)
- ☐ After the mailing date of a first Office Action but before (1) mailing of a final action under 37 C.F.R. §1.113; or (2) mailing of a notice of allowance under §1.311, whichever occurs first.
- ☐ Payment for the fee set forth in 37 C.F.R. §1.17(p) accompanies this submission; or
- ☐ The certification specified in 37 C.F.R. §1.97(e) is made below. (No fee is required.)
- ☐ After the mailing of (1) a final action under 37 C.F.R. §1.113; or (2) a notice of allowance under 37 C.F.R. §1.311 whichever occurs first, but **before** payment of the issue fee. The certification specified in 37 C.F.R. §1.97(e) is made below. The Commissioner hereby is petitioned to consider the Information Disclosure Statement accompanying this submission. Payment for the Petition fee set forth in 37 C.F.R. §1.17(i)(1) accompanies this submission.
- ☐ The undersigned counsel for applicant(s) hereby certifies each item of information identified in the Information Disclosure Statement was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
- ☐ The undersigned counsel for applicant(s) hereby certifies that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign Patent Office in a counterpart foreign application, or to the knowledge of the undersigned, after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
- ☐ PTO Form 2038 to charge filing fee of \$0.00 to Sonnenschein's American Express Account.

Serial No.: 10/722,292



The Commissioner is hereby authorized to charge any deficiency in fees which may be required, or credit any overpayment to Account No. 19-3140. *A duplicate copy of this sheet is enclosed for this purpose.*

Very respectfully,

SONNENSCHN NATH & ROSENTHAL LLP

By *Daniel W. Celander*, Reg. 52,710

Daniel W. Celander, Ph.D.

Sonnenschein, Nath & Rosenthal LLP

P.O. Box 061080, Wacker Drive Station, Sears Tower

Chicago, Illinois 60606

Telephone (312) 876-8000

When phoning re this application,
please call (312) 876-8071.

CERTIFICATE OF MAILING

I hereby certify that this Information Disclosure Statement is being deposited with the United States Postal Service in an envelope addressed to Mail Stop DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. on DEC. 18, 2003.

Daniel W. Celander

Daniel W. Celander, Ph.D.



Our File No. 09800080-0174

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Shimkets *et al.*

Application No.: 10/722,292

Filed: November 25, 2003

For: METHOD OF DETECTING
CARDIAC HYPERTROPHY
THROUGH PROBE
HYBRIDIZATION AND GENE
EXPRESSION ANALYSIS

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

In accordance with the provisions of 37 C.F.R. § 1.56, Applicants request that citation and examination of the references identified on the attached PTO-1449 form, copies of which are enclosed herewith in accordance with 37 C.F.R. §1.98, be made during the course of examination of the above-referenced application for United States Letters Patent.

EXPLANATION OF RELEVANCE

References A1, B1, and C1 through C99 were filed in Serial No. 09/554,169 filed on August 21, 2000, which is the parent for this new divisional application. Copies of the cited references are enclosed.

SONNENSCHN NATH & ROSENTHAL LLP
P. O. BOX 061080
Wacker Drive Station, Sears Tower
CHICAGO, IL 60606
(312) 876-8071 (Phone)
(312) 876-7934 (Fax)
dcclander@sonnenschnein.com (Email)

Respectfully submitted,



Daniel W. Celander, Ph.D.
Registration No. 52,710

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of info unless it contains a valid OMB control no.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/722,292
				Filing Date	November 25, 2003
				First Named Inventor	Richard A. Shimkets <i>et al.</i>
				Group Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	10	Attorney Docket Number	09800080-0174

U.S. PATENT DOCUMENTS						
Examiner Initials*	CiteNo. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A1	5,679,545		Joffe Baker et al.	10-21-1997	

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
✓	B1	WIPO	WO 99/24571	A2	CuraGen Corporation	05-20-1999		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

14349674/v1

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ☐

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, persons are not required to respond to a collection of info unless it contains a valid OMB control no.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 10

Complete if Known

Application Number	10/722,292
Filing Date	November 25, 2003
First Named Inventor	Richard A. Shimkets <i>et al.</i>
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	09800080-0174

OTHER ITEMS – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	CiteNo. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog <i>etc.</i>), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
✓	C1	Achyuthan, K. <i>et al.</i> , "Immunochemical analyses of human plasma fibronectin-cytosolic transglutaminase interactions," <i>J. Immuno. Methods</i> , 180:69-79 (1995).	
✓	C2	Anversa P. <i>et al.</i> , "Stereological Measurement of Cellular and Subcellular Hypertrophy and Hyperplasia in the Papillary Muscle of Adult Rat," <i>J. Mol. Cell. Cardiol.</i> , 12:781-795 (1980).	
✓	C3	Batra, S. and K. Rakusan, "Capillarization of the Hypertrophic Heart: Discrepancy of the Results Obtained by the Triangulation and Domain Methods," <i>J. Cardiovasc. Pharmacol.</i> , 17 (Suppl. 2):S151-S153 (1991).	
✓	C4	Berthod, F. <i>et al.</i> , "Differential Expression of Collagens XII and XIV in Human Skin and in Reconstructed Skin," <i>J. Invest. Dermatol.</i> , 108(5):737-742 (1997).	
✓	C5	Bhalerao, J. <i>et al.</i> , "Molecular Cloning, Characterization, and Genetic Mapping of the cDNA Coding for a Novel Secretory Protein of Mouse," <i>J. Biol. Chem.</i> , 270:16385-16394 (1995).	
✓	C6	Black, F. <i>et al.</i> , "The Vascular Smooth Muscle α -Actin Gene is Reactivated during Cardiac Hypertrophy Provoked by Load," <i>J. Clin. Invest.</i> , 88:1581-1588 (1991).	
✓	C7	Boheler, K. and K. Schwartz, "Gene Expression in Cardiac Hypertrophy," <i>Trends Cardiovasc. Med.</i> 2(5):176-182 (1992).	
✓	C8	Boluyt, M. <i>et al.</i> , "Alterations in Cardiac Gene Expression During the Transition From Stable Hypertrophy to Heart Failure," <i>Circ. Res.</i> , 75:23-32 (1994).	
✓	C9	Bonaldo, M. <i>et al.</i> , GenBank Accession No. AA818324, 02-18-1998.	
✓	C10	Burgess, M. <i>et al.</i> , "Exercise- and hypertension-induced collagen changes are related to left ventricular function in rat hearts," <i>Am. J. Physiol.</i> , 270(1 pt 2):(H151-H159) (1996).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ☐

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of info unless it contains a valid OMB control no.

Substitute for form 1449A/PTO				C mplete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/722,292
				Filing Date	November 25, 2003
				First Named Inventor	Richard A. Shimkets <i>et al.</i>
				Group Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	3	of	10	Attorney Docket Number	09800080-0174
OTHER ITEMS – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	CiteNo.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T²
✓	C11	Buttrick, P. <i>et al.</i> , "Alterations in Gene Expression in the Rat Heart after Chronic Pathological and Physiological Loads," <i>J. Mol. Cell. Cardiol.</i> , 26:61-67 (1994).			
✓	C12	Calderone H. <i>et al.</i> , "Pressure and Volume-Induced Left Ventricular Hypertrophies are Associated with Distinct Myocyte Phenotypes and Differential Induction of Peptide Growth Factor mRNAs," <i>Circulation</i> , 92:2385-2390 (1995).			
✓	C13	Chapman, D. <i>et al.</i> , "Regulation of Fibrillar Collagen Types I and III and Basement Membrane Type IV Collagen Gene Expression in Pressure Overloaded Rat Myocardium," <i>Circ. Res.</i> , 67:787-794 (1990).			
✓	C14	Charlemagne, D. <i>et al.</i> , "Alteration of Na,K-ATPase Subunit mRNA and Protein Levels in Hypertrophied Rat Heart," <i>J. Biol. Chem.</i> , 269:1541-1547 (1994).			
✓	C15	Chien, K. <i>et al.</i> , "Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response," <i>FASEB</i> , 5:3037-3046 (1991).			
✓	C16	Chomczynski, P. <i>et al.</i> , "Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-Chloroform Extraction," <i>Anal. Biochem.</i> 162:156-159 (1987).			
✓	C17	Chomczynski, P. <i>et al.</i> , "A Reagent for the Single-Step Simultaneous Isolation of RNA, DNA and Proteins from Cell and Tissue Samples," <i>Biotechniques</i> , 15:532-534, 536-537 (1993).			
✓	C18	Comb, M. <i>et al.</i> , "Primary structure of the human Met- and Leu-enkephalin precursor and its mRNA," <i>Nature</i> , 295:663-666 (1982).			
✓	C19	Cooper, G. <i>et al.</i> , "Load Induction of Cardiac Hypertrophy," <i>J. Mol. Cell. Cardiol.</i> , 21 (Suppl. V):11-30 (1989).			
✓	C20	Cooper, G., "Cardiocyte Adaptation to Chronically Altered Load," <i>Ann. Rev. Physiol.</i> , 49:501-518 (1987).			
✓	C21	Cummins, P., "Transitions in human atrial and ventricular myosin light-chain isoenzymes in response to cardiac-pressure-overload-induced hypertrophy," <i>Biochem. J.</i> , 205:195-204 (1982).			

Please type a plus sign (+) inside this box ☐

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of info unless it contains a valid OMB control no.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/722,292
				Filing Date	November 25, 2003
				First Named Inventor	Richard A. Shimkets <i>et al.</i>
				Group Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	4	of	10	Attorney Docket Number	09800080-0174
OTHER ITEMS – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	CiteNo.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog <i>etc.</i>), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
✓	C22	de Fatima Bonaldo, M. <i>et al.</i> , "Normalization and Subtraction: Two Approaches to Facilitate Gene Discovery," <i>Genome Res.</i> , 6:791-806 (1996).			
✓	C23	de la Bastie, D. <i>et al.</i> , "Function of the Sarcoplasmic Reticulum and Expression of Its Ca ²⁺ -ATPase Gene in Pressure Overload-Induced Cardiac Hypertrophy in the Rat," <i>Circ. Res.</i> , 66:554-564 (1990).			
✓	C24	Delcayre, C. <i>et al.</i> , "Synthesis of Stress Proteins in Rat Cardiac Myocytes 2-4 Days after Imposition of Hemodynamic Overload," <i>J. Clin. Invest.</i> , 82:460-468 (1988).			
✓	C25	Desjardins S, Mueller RW, Cauchy MJ. "A pressure overload model of congestive heart failure in rats," <i>Cardiovasc. Res.</i> 22:696-702 (1988).			
✓	C26	Donohue, T. <i>et al.</i> , "Induction of Myocardial Insulin-Like Growth Factor-I Gene Expression in Left Ventricular Hypertrophy," <i>Circulation</i> , 89:799-809 (1994).			
✓	C27	Dreher, K. <i>et al.</i> , "Vascular smooth muscle biglycan represents a highly conserved proteoglycan within the arterial wall," <i>Eur. J. Cell Biol.</i> , 53:296-304 (1990).			
✓	C28	Eghbali, M. <i>et al.</i> , "Localization of Types I, III and IV Collagen mRNAs in Rat Heart Cells by <i>in situ</i> Hybridization," <i>J. Mol. Cell. Cardiol.</i> , 21:103-113 (1989).			
✓	C29	Engelmann, G. <i>et al.</i> , "Immediate postnatal rat heart development modified by abdominal aortic banding: Analysis of gene expression," <i>Mol. Cell. Biochem.</i> , 163/164:47-56 (1996).			
✓	C30	Eppenberger, H. <i>et al.</i> , "Adult Rat Cardiomyocytes in Culture, A Model System to Study the Plasticity of the Differentiated Cardiac Phenotype at the Molecular and Cellular Levels," <i>Trends Cardiovasc. Med.</i> 4:187-193 (1994).			
✓	C31	Feldman, A. <i>et al.</i> , "Selective Changes in Cardiac Gene Expression During Compensated Hypertrophy and the Transition to Cardiac Decompensation in Rats With Chronic Aortic Banding," <i>Circ. Res.</i> , 73:184-192 (1993).			
✓	C32	Feldman, A.M., "Can we alter survival in patients with congestive heart failure?" <i>JAMA</i> 267:1956-1961 (1992).			

Please type a plus sign (+) inside this box ☐

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of info unless it contains a valid OMB control no.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/722,292
				Filing Date	November 25, 2003
				First Named Inventor	Richard A. Shimkets <i>et al.</i>
				Group Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	5	of	10	Attorney Docket Number	09800080-0174
OTHER ITEMS – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	CiteNo.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog <i>etc.</i>), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T²
✓	C33	Grossman, W. <i>et al.</i> , "Wall Stress and Patterns of Hypertrophy in the Human Left Ventricle," <i>J. Clin. Invest.</i> 56:56-64 (1975).			
✓	C34	Hasenfuss, G. "Animal models of human cardiovascular disease, heart failure and hypertrophy," <i>Cardiovasc. Res.</i> 39:60-76 (1998).			
✓	C35	Heimer, R. <i>et al.</i> , "TGF- β Modulates the Synthesis of Proteoglycans by Myocardial Fibroblasts in Culture," <i>J. Mol. Cell. Cardiol.</i> , 27:2191-2198 (1995).			
✓	C36	Ingwall, J., "Is Cardiac Failure a Consequence of Decreased Energy Reserve?" <i>Circulation</i> , 87 (Suppl.) VII58 - VII62 (1993).			
✓	C37	Ingwall, J. <i>et al.</i> , "The Creative Kinase System in Normal and Diseased Human Myocardium," <i>N. Engl. J. Med.</i> , 313:1050-1054 (1985).			
✓	C38	Ito, H. <i>et al.</i> , "Endothelin-1 Is an Autocrine/Paracrine Factor in the Mechanism of Angiotensin II-induced Hypertrophy in Cultured Rat Cardiomyocytes," <i>J. Clin. Invest.</i> , 92:398-403 (1993).			
✓	C39	Iwaki, K. <i>et al.</i> , " α - and β -Adrenergic Stimulation Induces Distinct Patterns of Immediate Early Gene Expression in Neonatal Rat Myocardial Cells," <i>J. Biol. Chem.</i> , 265:13809-13817 (1990).			
✓	C40	Izumo, S. <i>et al.</i> , "Protooncogene Induction and Reprogramming of Cardiac Gene Expression Produced by Pressure Overload," <i>Proc. Natl. Acad. Sci. USA</i> , 85:339-343 (1988).			
✓	C41	Johnson, T. <i>et al.</i> , "The Role of Transglutaminase in the Rat Subtotal Nephrectomy Model of Renal Fibrosis," <i>J. Clin. Invest.</i> , 99:2950-2960 (1997).			
✓	C42	Kadenbach, B. <i>et al.</i> , "Separation of Mammalian Cytochrome c Oxidase into 13 Polypeptides by a Sodium Dodecyl Sulfate-Gel Electrophoretic Procedure," <i>Anal. Biochem.</i> , 129:517-521 (1983).			
✓	C43	Kannel, W., "Epidemiological Aspects of Heart Failure," <i>Cardiol. Clin.</i> , 7:1-9 (1989).			
✓	C44	Katz, A., "Scientific Insights from Clinical Studies of Converting-Enzyme Inhibitors in the Failing Heart," <i>Trends Cardiovasc. Med.</i> , 5:37-44 (1995).			

Please type a plus sign (+) inside this box ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of info unless it contains a valid OMB control no.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/722,292
				Filing Date	November 25, 2003
				First Named Inventor	Richard A. Shimkets <i>et al.</i>
				Group Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	6	of	10	Attorney Docket Number	09800080-0174
OTHER ITEMS – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	CiteNo.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
✓	C45	Keller, A. <i>et al.</i> , "Differential expression of α - and β -enolase genes during rat heart development and hypertrophy," <i>Am. J. Physiol.</i> , 269:H1843-H1851 (1995).			
✓	C46	Kimura, S. <i>et al.</i> , "Sarcoplasmic reticulum function in skinned fibers of hypertrophied rat ventricle," <i>Am. J. Physiol.</i> , 256:H1006-H1011 (1989).			
✓	C47	Knowlton, K. <i>et al.</i> , "Co-regulation of the Atrial Natriuretic Factor and Cardiac Myosin Light Chain-2 Genes during α -Adrenergic Stimulation of Neonatal Rat Ventricular Cells," <i>J. Biol. Chem.</i> , 266:7759-7768 (1991).			
✓	C48	Komuro, I. <i>et al.</i> , "Expression of Cellular Oncogenes in the Myocardium During the Developmental Stage and Pressure-Overloaded Hypertrophy of the Rat Heart," <i>Circ. Res.</i> , 62:1075-1079 (1988).			
✓	C49	Komuro, I. <i>et al.</i> , "Molecular Cloning and Characterization of a Ca^{2+} + Mg^{2+} - dependent Adenosine Triphosphatase from Rat Cardiac Sarcoplasmic Reticulum. Regulation of Its Expression by Pressure Overload and Developmental Stage," <i>J. Clin. Invest.</i> , 83:1102-1108 (1989).			
✓	C50	König, M. <i>et al.</i> , "Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin," <i>Nature</i> , 383:535-538 (1996).			
✓	C51	Konstam, M. <i>et al.</i> , "Effects of the Angiotensin Converting Enzyme Inhibitor Enalapril on the Long-term Progression of Left Ventricular Dysfunction in Patients With Heart Failure," <i>Circulation</i> , 86:431-438 (1992).			
✓	C52	Lai, J. <i>et al.</i> , "Prostaglandin $\text{F}_{2\alpha}$ induces cardiac myocyte hypertrophy in vitro and cardiac growth in vivo," <i>Am. J. Physiol.</i> , 271:H2197-H2208 (1996).			
✓	C53	Lee, H. <i>et al.</i> , " α_1 -Adrenergic Stimulation of Cardiac Gene Transcription in Neonatal Rat Myocardial Cells Effects on Myosin Light Chain-2 Gene Expression," <i>J. Biol. Chem.</i> 263:7352-7358 (1988).			
✓	C54	Legon, S. <i>et al.</i> , "The structure and expression of the preproenkephalin gene," <i>Nucl. Acids Res.</i> , 10:7905-7918 (1982).			
✓	C55	Lindy, S. <i>et al.</i> , "Protocollagen Proline Hydroxylase Activity in Rat Heart During Experimental Cardiac Hypertrophy," <i>Circ. Res.</i> 30:205-209 (1972).			

Please type a plus sign (+) inside this box ☐

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of info unless it contains a valid OMB control no.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/722,292
				Filing Date	November 25, 2003
				First Named Inventor	Richard A. Shimkets <i>et al.</i>
				Group Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	7	of	10	Attorney Docket Number	09800080-0174
OTHER ITEMS – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	CiteNo.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
✓	C56	Liu, X. <i>et al.</i> , "Type III collagen is crucial for collagen I fibrillogenesis and for normal cardiovascular development," <i>Proc. Natl. Acad. Sci. USA</i> , 94:1852-1856 (1997).			
✓	C57	Lockard, V. and S. Bloom, "Trans-cellular Desmin-Lamin B Intermediate Filament Network in Cardiac Myocytes," <i>J. Mol. Cell. Cardiol.</i> , 25:303-309 (1993).			
✓	C58	Lompré, A-M. <i>et al.</i> , "Changes in Gene Expression during Cardiac Growth," <i>Int. Rev. Cytol.</i> , 124:137-186 (1991).			
✓	C59	Macalma, T. <i>et al.</i> , "Molecular Characterization of Human Zyxin," <i>J. Biol. Chem.</i> , 271:31470-31478 (1996).			
✓	C60	Maeda, K. <i>et al.</i> , "Analysis of an expression profile of genes in the human adipose tissue," <i>Gene</i> , 190:227-235 (1997).			
✓	C61	Mercadier, J. <i>et al.</i> , "Myosin Isoenzymic Changes in Several Models of Rat Cardiac Hypertrophy," <i>Circ. Res.</i> , 49:525-532 (1981).			
✓	C62	Mercadier, J. <i>et al.</i> , "Altered Sarcoplasmic Reticulum CA ²⁺ -ATPase Gene Expression in the Human Ventricle during End-Stage Heart Failure," <i>J. Clin. Invest.</i> , 85:305-309 (1990).			
✓	C63	Morgan, H. and K. Baker, "Cardiac Hypertrophy. Mechanical, Neural, and Endocrine Dependence," <i>Circulation</i> , 83:13-25 (1991).			
✓	C64	Morkin, E. and T. Ashford, "Myocardial DNA synthesis in experimental cardiac hypertrophy," <i>Am. J. Physiol.</i> , 215:1409-1413 (1968).			
✓	C65	Murakami, Y. <i>et al.</i> , "Cloning of Antizyme Inhibitor, a Highly Homologous Protein to Ornithine Decarboxylase," <i>J. Biol. Chem.</i> , 271:3340-3342 (1996).			
✓	C66	Nagai, R. <i>et al.</i> , "Regulation of Myocardial CA ²⁺ -ATPase and Phospholamban mRNA Expression in Response to Pressure Overload and Thyroid Hormone," <i>Proc. Natl. Acad. Sci. USA</i> , 86:2966-2970 (1989).			
✓	C67	Nurminskaya, M. & T. Linsenmayer, "Identification and Characterization of Up-Regulated Genes During Chondrocyte Hypertrophy," <i>Devel. Dyn.</i> , 206:260-271 (1996).			

Please type a plus sign (+) inside this box ☐

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of info unless it contains a valid OMB control no.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Applicant Number	10/722,292
				Filing Date	November 25, 2003
				First Named Inventor	Richard A. Shimkets <i>et al.</i>
				Group Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	8	of	10	Attorney Docket Number	09800080-0174
OTHER ITEMS – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	CiteNo.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
✓	C68	Pennica, D. <i>et al.</i> , "Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy," <i>Proc. Natl. Acad. Sci. USA</i> , 92:1142-1146 (1995).			
✓	C69	Pouleur, H., "Immediate and delayed mechanisms of cardiac adaptation to a haemodynamic overload." In <u>Research in Cardiac Hypertrophy and Failure</u> , Swynghedauw, B., INSERM/John Libbey Eurotext, pp. 401-413 (1990).			
✓	C70	Reinhard, M. <i>et al.</i> , "VASP interaction with vinculin: a recurring theme of interactions with proline-rich motifs," <i>FEBS Lett.</i> , 399:103-107 (1996).			
✓	C71	Rockman, H. <i>et al.</i> , "Segregation of Atrial-Specific and Inducible Expression of an Atrial Natriuretic Factor Transgene in an in vivo Murine Model of Cardiac Hypertrophy," <i>Proc. Natl. Acad. Sci. USA</i> , 88:8277-8281 (1991).			
✓	C72	Sage, E. H., "Terms of attachment: SPARC and tumorigenesis," <i>Nature Med.</i> , 3:144-146 (1997).			
✓	C73	Samuel, J. <i>et al.</i> , "Accumulation of Fetal Fibronectin mRNAs during the Development of Rat Cardiac Hypertrophy Induced by Pressure Overload," <i>J. Clin. Invest.</i> , 88:1737-1746 (1991).			
✓	C74	Schmeichel, K. and M. Berkerle, "Molecular Dissection of a LIM Domain," <i>Mol. Biol. Cell</i> , 8:219-230 (1997).			
✓	C75	Schneider, M. <i>et al.</i> , "Modulation of Cardiac Genes by Mechanical Stress," <i>Mol. Biol. Med.</i> , 8:167-183 (1991).			
✓	C76	Schönherr, E. <i>et al.</i> , "Interaction of Biglycan with Type I Collagen," <i>J. Biol. Chem.</i> , 270:2776-2783 (1995).			
✓	C77	Shoffner, J. and D. Wallace, "Oxidative Phosphorylation Diseases and Mitochondrial DNA Mutations: Diagnosis and Treatment," <i>Annu. Rev. Nutr.</i> , 14:535-568 (1994).			
✓	C78	Shoffner, J.M. and D.C. Wallace, "Oxidative Phosphorylation Disases," in <u>The Metabolic and Molecular Bases of Inherited Diseases</u> , (7 th ed.), Scriver, C.R. <i>et al.</i> (McGraw Hill), pp. 1535-1609, 1995.			
✓	C79	Schwartz, K. <i>et al.</i> , "Modifications of Gene Expression in Cardiac Hypertrophy," <i>Heart Failure</i> , 4:154-163 (1988).			

Please type a plus sign (+) inside this box ☐

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of info unless it contains a valid OMB control no.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/722,292
				Filing Date	November 25, 2003
				First Named Inventor	Richard A. Shimkets <i>et al.</i>
				Group Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	9	of	10	Attorney Docket Number	09800080-0174
OTHER ITEMS – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	CiteNo.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
✓	C80	Shimkets, R.A. <i>et al.</i> "Gene expression analysis by transcript profiling coupled to a gene database query" <i>Nat. Biotechnol.</i> 17:798-803 (1999).			
✓	C81	Shubeita, H. <i>et al.</i> , "Endothelin Induction of Inositol Phospholipid Hydrolysis, Sarcomere Assembly, and Cardiac Gene Expression in Ventricular Myocytes," <i>J. Biol. Chem.</i> , 265:20555-20562 (1990).			
✓	C82	Simpson, P., "Norepinephrine-stimulated Hypertrophy of Cultured Rat Myocardial Cells Is an Alpha ₁ Adrenergic Response," <i>J. Clin. Invest.</i> , 72:732-738 (1983).			
✓	C83	Simpson P. <i>et al.</i> , "Transcription of Early Developmental Isogenes in Cardiac Myocyte Hypertrophy," <i>J. Mol. Cell. Cardiol.</i> , 21, (Suppl. V):79-89 (1989).			
✓	C84	Soares, M.B. <i>et al.</i> , GenBank Accession No. AA818324, 02-17-98.			
✓	C85	Swynghedauw, B., "Developmental and Functional Adaptation of Contractile Proteins in Cardiac and Skeletal Muscles," <i>Physiol. Rev.</i> , 66:710-771 (1986).			
✓	C86	Takeda, K. <i>et al.</i> , "Effect of an Angiotensin II Receptor Antagonist, TCV-116, on Cardiac Hypertrophy and Coronary Circulation in Spontaneously Hypertensive Rats," <i>Blood Pressure</i> , 3, (Supp 5) 94-98 (1994).			
✓	C87	Tamura, K. <i>et al.</i> , "Cyclin G: a new mammalian cyclin with homology to fission yeast Cig1," <i>Oncogene</i> , 8:2113-2118 (1993).			
✓	C88	Tanaka, J. <i>et al.</i> , "Nitric Oxide-Mediated cGMP Synthesis in Oligodendrocytes in the Developing Rat Brain," <i>GLIA</i> , 19:286-297 (1997).			
✓	C89	Tremble, P. <i>et al.</i> , "SPARC, a Secreted Protein Associated with Morphogenesis and Tissue Remodeling, Induces Expression of Metalloproteinases in Fibroblasts Through a Novel Extracellular Matrix-dependent Pathway," <i>J. Cell. Biol.</i> 121:1433-1444 (1993).			
✓	C90	Turto, H., "Collagen metabolism in experimental cardiac hypertrophy in the rat and the effect of digitoxin treatment," <i>Cardiovasc. Res.</i> , 11:358-366 (1977).			
✓	C91	van Groningen, J. <i>et al.</i> , "Rat desmin gene structure and expression," <i>Biochim. Biophys. Acta</i> , 1217:107-109 (1994).			

Please type a plus sign (+) inside this box ☐

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				C mplete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/722,292
				Filing Date	November 25, 2003
				First Named Inventor	Richard A. Shimkets <i>et al.</i>
				Group Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	10	of	10	Attorney Docket Number	09800080-0174
OTHER ITEMS – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	CiteNo.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T²
✓	C92	Wälchli, C. <i>et al.</i> , "Tissue-specific expression of the fibril-associated collagens XII and XIV," <i>J. Cell Sci.</i> , 107:669-681 (1994).			
✓	C93	Watkins, S.C. <i>et al.</i> , "Microtubules and Desmin Filaments During Onset of Heart Hypertrophy in Rat: A Double Immunoelectron Microscope Study," <i>Circ. Res.</i> , 60:327-336 (1987).			
✓	C94	Watson, P. <i>et al.</i> , "Desmin gene expression in cardiac myocytes is responsive to contractile activity and stretch," <i>Am. J. Physiol.</i> 270:C1228-C1235 (1996).			
✓	C95	Weber, K. and C. Brilla, "Pathological Hypertrophy and Cardiac Interstitium," <i>Circulation</i> , 83:1849-1865 (1991).			
✓	C96	Wegrowski, Y. <i>et al.</i> , "The Murine Biglycan: Complete cDNA Cloning, Genomic Organization, Promoter Function, and Expression," <i>Genomics</i> , 30:8-17 (1995).			
✓	C97	Yan, S. <i>et al.</i> , "An intracellular protein that binds amyloid- β peptide and mediates neurotoxicity in Alzheimer's disease," <i>Nature</i> , 389:689-695 (1997).			
✓	C98	Yan, S. <i>et al.</i> , GenBank Accession No. U96116, 05-13-97.			
✓	C99	Yan, S. <i>et al.</i> , GenBank Accession No. U96132, 11-01-97.			
✓	C 100	International Search Report mailed 31 March 1999 in corresponding International Application No. PCT/US98/23953, now Publication No. WO 99/24571, reference B1 herein.			

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--